Sanofi 's ( SNY ) diabetes segment has been performing well spearheaded by its lead product Lantus. Lantus sales are on the rise. The diabetes segment was further boosted by the EU approval of Lyxumia (lixisenatide) in Feb 2013. The EC approved Lyxumia in combination with oral glucose-lowering medicinal products and/or basal insulin when these, in combination with lifestyle management, did not provide adequate glycemic control. In the second quarter of 2013, the drug generated sales of approximately €1 million. In September, Sanofi announced its decision to withdraw the new drug application (:NDA) for lixisenatide in the U.S. Sanofi was looking to get the drug approved for type II diabetes. The NDA included early interim data from the ongoing ELIXA cardiovascular (:CV) outcomes study. The company believes that potential public disclosure will hamper the integrity of the ELIXA CV study, which is expected to complete in the next 15 months.